To determine whether an
Crohn's disease is a chronic disease characterised by recurrent acute attacks and remissions. Body weight loss and malnutrition are commonly recognised complications in patients with Crohn's disease. Nutritional support is often required during the course of the disease. As a first step, total parenteral nutrition has been used successfully as primary treatment in hopes of achieving both improvement of nutritional status and remission of the acute attacks.' 2 Considering the complications and difficulties of parenteral nutrition, enteral nutrition is a preferable method of nutritional support when possible. Some clinical experiences have shown that an elemental enteral diet (EED) is as effective as parenteral nutrition in inducing remission from active Crohn's disease.3-S As stated by O'Morain et al,5 EED represents an alternative to total parenteral nutrition not only from a nutritional point of view but also because EED may induce a functional and antigenic bowel rest. Recently, the role of bowel rest was questioned by the studies of Greenberg et a16 and Lochs et al, 7 who both found rates of clinical remission during partial parenteral nutrition associated with oral foods given without restriction similar to those during total parenteral nutrition. These studies suggested that nonelemental diets may allow remission in many patients without additional drug therapy.
Since EED is not always available and is twice as expensive as polymeric defined formula diets (PFD), we compared the efficacy of both EED and PFD on the nutritional status, and on disease activity in patients with active Crohn's disease in a prospective randomised therapeutic trial in 30 patients.
Methods

PATIENTS
Thirty patients with Crohn's disease diagnosed by previously reported clinical, morphological, and pathological criteria8 participated in the study. The patients were randomly assigned to one of the two groups, EED or PFD, if no exclusion critera were noted. Fourteen patients were in Rothschild Hospital and 16 in Bichat Hospital. The characteristics of the patients are shown in Table I . The In order to obtain a larger number of patients, the study was performed in two centres. We analysed a centre effect for each comparison of the variables tested using analysis of variance with the centre as covariable. There were no significant effects of the centre in any of the results that follow. Hence their individual identities in the current study was not deemed critical, and no distinction between the two centres is made when presenting the results of EED v PFD groups. All results are expressed as mean (SD). Significance of the differences between the two nutritional supports was determined by analysis of variance and analysis of covariance for all parametric variables. Differences in relapse rates between the two nutritional supports were checked by the Kaplan-Meier method. All these statistical analyses were performed using the MGLH module of Systat.13 108 (10) 113 (12) 120 (17) 117 (18) A dramatic decrease in faecal output was also observed early during both types of nutritional support: faecal output was 396 (147) g/day at inclusion (n=30), 232 (233) g/day at day 14 (n= 29), and 202 (207) g/day at day 28 (n=29) (p<0001 for day 14 and day 28 v day 0). The decrease in faecal output was similar in the two groups (Fig 2) .
Clearance of al antitrypsin showed a clear improvement through nutritional support in both groups (p<001), without any significant difference between EED and PFD groups: from 104 (65) to 56 (79) ml/day (n= 12) in the EED group and from 50 (26) to 31 (25) ml/day (n= 12) in the PFD group.
The colonoscopic lesions also improved during nutritional support (Table III) (1-8 kg) ) triceps skinfold (+0-8 (1F1) mm), creatinine index (+8 (15)%), and serum albumin (+1.7 (3.8) g/l). The other markers did not change significantly. No difference between the two types of nutritional support was evident for any of these nutritional markers (Table IV) .
FOLLOW-UP
At one month after discharge, 18 patients (nine in each group) had a CDAI less than 150, and five patients (two in EED and three in PFD group) had mild recurrent symptoms with a CDAI between 150 and 250.
During the next 12 months an obvious clinical relapse (CDAI>250), or a complication (n=2) occurred in 16 out of the 23 patients (70%). Two patients were treated surgically. There was no difference in the percentages of patients without obvious clinical relapse between the two groups (Fig 3) .
Discussion
The present study confirmed that enteral nutrition may be used as the primary treatment and as supportive therapy in active Crohn's disease: enteral nutrition induced clinical remission in about two thirds of the patients. In most of them the clinical improvement was associated with reduced inflammation and evidence of endoscopic improvement.
A continuous line of evidence suggests a therapeutic role for nutritional support, i.e. parenteral or enteral nutrition, in patients with Crohn's disease, after failure of standard medical treatment, when surgical treatment is not desirable. In active Crohn's disease, total parenteral nutrition was shown to induce clinical remissionin 57to 83% ofthepatients.' 2 O'Morain et al5 found that an elemental diet was as effective as prednisolone in achieving clinical remission.
Similarly, Saverymuttu et all4 and Lochs et al'
found that an elemental diet, alone or associated with non-absorbable antibiotics, was successful in active Crohn's disease.
The present study confirms the efficacy of an elemental diet: EED induced a clinical remission (CDAI< 150) in 66% of the patients after four weeks. (Fig 1) . This 
